Compare AMR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AMR | GPCR |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2017 | 2023 |
| Metric | AMR | GPCR |
|---|---|---|
| Price | $201.15 | $42.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $181.50 | $103.17 |
| AVG Volume (30 Days) | 234.7K | ★ 702.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,129,481,000.00 | N/A |
| Revenue This Year | $15.05 | N/A |
| Revenue Next Year | $14.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $104.42 | $15.80 |
| 52 Week High | $253.82 | $94.90 |
| Indicator | AMR | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 58.04 |
| Support Level | $198.13 | $42.72 |
| Resistance Level | $212.15 | $57.23 |
| Average True Range (ATR) | 13.44 | 2.11 |
| MACD | -0.77 | 0.93 |
| Stochastic Oscillator | 51.76 | 92.13 |
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.